LONDON, UK / ACCESSWIRE / October 5, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Merck & Co., Inc. (NYSE: MRK) (“Merck”), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=MRK. The Company announced on October 03, 2017, that it would present new data from its chronic hepatitis C clinical development programs and real-world studies at The Liver Meeting® 2017. For immediate access to our complimentary reports, including today’s coverage, register for free now at:
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on MRK. Go directly to your stock of interest and access today’s free coverage at:
Merck plans to present the latest analyses of ZEPATIER (elbasvir and grazoprevir) in real-world scenario, and follow-up analyses from Phase-3 clinical trials, including results from the C-EDGE CO-STAR three-year observational follow-up study assessing chronic hepatitis C virus (HCV) reinfection incidence and risk behaviors in patients who were treated with ZEPATIER while on opioid agonist therapy.
ZEPATIER is a fixed-dose combination product that contains elbasvir, a HCV NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor. In the US, it has already been recommended for the treatment of chronic HCV GT1 or 4 infection in adults. Besides, ZEPATIER is also recommended for use with ribavirin (RBV) in certain patient populations. However, it has not been indicated for the treatment of chronic HCV GT3 or GT6 infections. The US Prescribing Information for ZEPATIER comprises a Boxed Warning about the risk of hepatitis B virus (HBV) reactivation in patients co-infected with HCV and HBV.
As of now, ZEPATIER has been approved in more than 17 countries worldwide, including the United States, Canada, the European Union, Switzerland, Israel, Saudi Arabia, Australia, Japan, Vietnam, Georgia, Korea, New Zealand, Mexico, Taiwan, Egypt, Bahrain, and Argentina, while some additional regulatory approvals are anticipated.
Data Analysis for Real Word Application
Dr. Michael Robertson, Executive Director of Clinical Research, at Merck Research Laboratories, highlighted that the Company has been a leader in chronic hepatitis C for over 30 years. So far, Merck’s chronic HCV clinical development programs have included over 135 clinical trials in around 40 countries and have enrolled nearly 10,000 participants.
Now that there are several treatments such as ZEPATIER available in the market, the Company’s focus is more on understanding their application in the real world. Analysis of data from patients treated with ZEPATIER around the world offers critical insights that may help inform elimination efforts, mainly for difficult-to-treat populations.
Presentations at The International Liver Congress 2017
The Liver Meeting® 2017 will take place in Washington, D.C. from October 20, 2017, to October 24, 2017.
For ZEPATIER 50mg/100mg tablets
Data to be presented on Saturday, October 21, 2017
Results from the veterans’ affairs system – Effectiveness of elbasvir/grazoprevir in patients with chronic Hepatitis C and chronic kidney disease.
A post hoc analysis of 11 clinical trials – A practical approach to enhancing the efficacy of elbasvir/grazoprevir using baseline viral load in participants with Hepatitis C Virus Genotype 1a infection.
Retrospective data analyses from the Trio Network – Impact of treatment duration and Ribavirin addition on real-world effectiveness of elbasvir/grazoprevir in select patient subgroups with Genotype 1 Chronic Hepatitis C.
Real-world cost-effectiveness of elbasvir/grazoprevir in Treatment-Naive patients with Chronic Hepatitis C virus Genotype 1 in the United States.
Data to be presented on Sunday, October 22, 2017
An integrated analysis of data from 11 Phases-2/3 Trials – Safety and efficacy of elbasvir/grazoprevir in Asian participants with Hepatitis C Virus Genotypes 1 and 4 Infection.
Results from the German Hepatitis C Registry (DHC-R) – Co-Morbidities and clinically relevant drug-drug interactions in patients undergoing treatment of Chronic HCV Genotype 1 Infection with elbasvir /grazoprevir.
Utilization and effectiveness of elbasvir/grazoprevir in Treatment-Naive Genotype 1a Chronic Hepatitis C Virus patients’ with/without Baseline NS5A Resistance-Associated Substitutions.
An integrated analysis of twelve clinical trials – Safety and efficacy of elbasvir/grazoprevir in Hepatitis C Virus GT1- and GT4-infected participants 65 years and older.
Data to be presented on Monday, October 23, 2017
Co-STAR Part B – Hepatitis C Virus reinfection and injecting risk behavior following elbasvir/grazoprevir treatment in participants on Opiate Agonist Therapy.
Additional Studies of Note
Data to be presented on Saturday, October 21, 2017
A mathematical model using data from the C-EDGE CO-STAR Study – Epidemiologic impact of expanding chronic Hepatitis C treatment in People who Inject Drug (PWID) in the United States.
Economic burden of Chronic Hepatitis C in Medicaid and commercially insured patients in the United States.
The C-SCOPE Study – Perceived barriers related to the management of HCV infections among physicians prescribing Opioid Agonist Therapy.
Last Close Stock Review
Merck’s share price finished yesterday’s trading session at $64.60, marginally up 0.36%. A total volume of 6.41 million shares have exchanged hands. The Company’s stock price advanced 2.38% in the last three months, 1.62% in the past six months, and 3.43% in the previous twelve months. Additionally, the stock gained 9.73% since the start of the year. Shares of the Company have a PE ratio of 35.19 and have a dividend yield of 2.91%. The stock currently has a market cap of $176.90 billion.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily
Information contained on this page is provided by an independent third-party content provider. Frankly and this Station make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact email@example.com